Retrospective Cohort Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 28, 2023; 29(4): 692-705
Published online Jan 28, 2023. doi: 10.3748/wjg.v29.i4.692
Disease trends after Helicobacter pylori eradication based on Japanese nationwide claims and the health check-up database
Kazuhiro Mizukami, Kentaro Sugano, Tomomi Takeshima, Kazunari Murakami
Kazuhiro Mizukami, Kazunari Murakami, Department of Gastroenterology, Oita University, Oita 8795593, Japan
Kentaro Sugano, Department of Medicine, Jichi Medical University, Tochigi 3290498, Japan
Tomomi Takeshima, Milliman Inc., Tokyo 1020083, Japan
Author contributions: Sugano K contributed to the conception of the study; Sugano K, Takeshima T, and Murakami K contributed to the design of the study; Mizukami K, Sugano K, Takeshima T, and Murakami K contributed to the interpretation of data; Mizukami K and Takeshima T wrote the article; Sugano K and Murakami K critically reviewed the manuscript.
Institutional review board statement: The study was reviewed and approved for publication by the Ethics Committee of Oita University, Faculty of Medicine (No. 1692).
Informed consent statement: Informed consent was not obtained because this study used anonymized claims data.
Conflict-of-interest statement: Sugano K received lecture fees from Takeda Pharma. Inc and he is an advisor of Phathom Co. Takeshima T is an employee of Milliman Inc., which provides consulting service for biomedical companies. Mizukami K and Murakami K declare that they have no conflicts of interest.
Data sharing statement: Data will not be made available to other researchers because access to the raw data is strictly limited to authorized researchers, and the raw data and interim analysis data must be deleted after the authorized research period. Analytic methods and analysis results approved for publication by the Ministry of Health, Labour and Welfare in Japan will be made available upon reasonable request.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kazuhiro Mizukami, MD, PhD, Associate Professor, Department of Gastroenterology, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita 8795593, Japan. mizkaz0809@oita-u.ac.jp
Received: October 29, 2022
Peer-review started: October 29, 2022
First decision: November 14, 2022
Revised: November 28, 2022
Accepted: January 9, 2023
Article in press: January 9, 2023
Published online: January 28, 2023
Core Tip

Core Tip: While Helicobacter pylori (H. pylori) eradication can prevent certain diseases including peptic ulcer diseases and gastric cancer, unfavorable effects of eradication therapy have also been reported. We analyzed a Japanese nationwide health claims database containing almost all health insurance claims data to compare the incidence and prevalence of specific diseases before and after H. pylori eradication to comprehensively assess its effects. We identified 5219731 patients who received primary eradication therapy. H. pylori eradication drastically reduced peptic ulcers and gastritis but was associated with an increase in Barrett’s esophagus, inflammatory bowel disease, allergic disease, and metabolic syndrome.